The search for surrogates - physiologic imaging in a breast cancer xenograft model during treatment with SU11248

被引：0
|
作者：
Miller, KD [1 ]
Miller, M [1 ]
Mehrotra, S [1 ]
Hutchins, G [1 ]
Badve, S [1 ]
Murray, LJ [1 ]
Sledge, GW [1 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
38
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] Preclinical evaluation of the tyrosine kinase inhibitor SU11248 for the treatment of breast cancer
    Abrams, TJ
    Murray, LJ
    Pryer, NK
    Garcia, R
    Potapova, O
    Laird, AD
    Manning, JWC
    Pesenti, E
    Cherrington, JM
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S75 - S75
  • [2] SU11248 inhibit the cancer growth factor and antiangiogenic in Xenograft of ovarian carcinoma mouse model
    Bauerschlag, D. O.
    Schein, C.
    Tiwari, S.
    Meinhold-Heerlein, I
    Jonat, W.
    Maass, N.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S61 - S61
  • [3] SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model
    Bauerschlag, D. O.
    Schem, C.
    Tiwari, S.
    Meinhold-Heerlein, I.
    Mundhenke, C.
    Weigel, M.
    Egberts, J. H.
    Kalthoff, H.
    Jonat, W.
    Maass, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
    Alyssa M Morimoto
    Nguyen Tan
    Kristina West
    Grant McArthur
    Guy C Toner
    William C Manning
    Beverly D Smolich
    Julie M Cherrington
    Oncogene, 2004, 23 : 1618 - 1626
  • [5] Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies
    Deprimo, Samuel E.
    Toner, Guy
    Mitchell, Paul
    De Boer, Richard
    Gibbs, Peter
    Hicks, Rodney
    McArthur, Grant
    Brega, Nicoletta
    McCarthy, Timothy
    Bello, Carlo
    CANCER RESEARCH, 2006, 66 (08)
  • [6] Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
    Morimoto, AM
    Tan, N
    West, K
    McArthur, G
    Toner, GC
    Manning, WC
    Smolich, BD
    Cherrington, JM
    ONCOGENE, 2004, 23 (08) : 1618 - 1626
  • [7] Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase
    Wang, JQ
    Miller, KD
    Sledge, GW
    Zheng, QH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (19) : 4380 - 4384
  • [8] SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Murray, LJ
    Abrams, TJ
    Long, KR
    Ngai, TJ
    Olson, LM
    Hong, WR
    Keast, PK
    Brassard, JA
    O'Farrell, AM
    Cherrington, JM
    Pryer, NK
    CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (08) : 757 - 766
  • [9] SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Lesley J. Murray
    Tinya J. Abrams
    Kelly R. Long
    Theresa J. Ngai
    Lisa M. Olson
    Weiru Hong
    Paul K. Keast
    Jacqueline A. Brassard
    Anne Marie O'Farrell
    Julie M. Cherrington
    Nancy K. Pryer
    Clinical & Experimental Metastasis, 2003, 20 : 757 - 766
  • [10] Nonclinical safety evaluation of sunitinib (SU11248; SUTENT), a novel multitargeted tyrosine kinase inhibitor for treatment of cancer
    Patyna, S.
    Heward, J. K.
    Evering, W.
    TOXICOLOGIC PATHOLOGY, 2007, 35 (01) : 188 - 188
12345